D.A. Davidson & CO. Invests $1.02 Million in BioLife Solutions, Inc. (NASDAQ:BLFS)

D.A. Davidson & CO. purchased a new stake in BioLife Solutions, Inc. (NASDAQ:BLFS) during the third quarter, according to its most recent disclosure with the SEC. The firm purchased 40,660 shares of the medical equipment provider’s stock, valued at approximately $1,018,000.

Several other institutional investors also recently bought and sold shares of BLFS. Vanguard Group Inc. boosted its stake in BioLife Solutions by 11.5% during the 1st quarter. Vanguard Group Inc. now owns 2,868,335 shares of the medical equipment provider’s stock worth $53,208,000 after purchasing an additional 296,727 shares during the last quarter. Fred Alger Management LLC boosted its position in BioLife Solutions by 6.0% during the second quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock worth $33,841,000 after acquiring an additional 88,840 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in BioLife Solutions by 9.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 794,971 shares of the medical equipment provider’s stock valued at $17,034,000 after acquiring an additional 66,422 shares in the last quarter. Curi RMB Capital LLC raised its holdings in BioLife Solutions by 0.5% in the 3rd quarter. Curi RMB Capital LLC now owns 421,933 shares of the medical equipment provider’s stock valued at $10,565,000 after acquiring an additional 2,283 shares during the last quarter. Finally, Mutual of America Capital Management LLC purchased a new position in BioLife Solutions in the 2nd quarter worth approximately $8,592,000. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at BioLife Solutions

In other news, CRO Garrie Richardson sold 3,070 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $25.12, for a total value of $77,118.40. Following the transaction, the executive now directly owns 114,773 shares in the company, valued at approximately $2,883,097.76. This represents a 2.61 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Aby J. Mathew sold 17,604 shares of BioLife Solutions stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $20.05, for a total transaction of $352,960.20. Following the completion of the sale, the executive vice president now owns 284,442 shares of the company’s stock, valued at $5,703,062.10. This trade represents a 5.83 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,313 shares of company stock worth $1,572,899. 2.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

BLFS has been the subject of a number of analyst reports. Northland Securities upped their price target on BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Craig Hallum upped their target price on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. TD Cowen lifted their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, HC Wainwright dropped their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a report on Monday, November 18th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $27.50.

BioLife Solutions Price Performance

NASDAQ:BLFS opened at $27.47 on Monday. BioLife Solutions, Inc. has a 52 week low of $11.91 and a 52 week high of $28.88. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $1.27 billion, a P/E ratio of -25.92 and a beta of 1.88. The stock’s fifty day moving average is $24.23 and its two-hundred day moving average is $23.24.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.